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Study Objectives: Recently, antibodies to the hypocretin receptor 2 (HCRTR2-Abs) were reported in a high proportion of  narcolepsy patients who 
developed the disease following Pandemrix® vaccination. We tested a group of  narcolepsy patients for the HCRTR2-Abs using a newly established cell-
based assay.
Methods: Sera from 50 narcolepsy type 1 (NT1) and 11 narcolepsy type 2 (NT2) patients, 22 patients with other sleep disorders, 15 healthy controls, and 93 
disease controls were studied. Cerebrospinal fluid (CSFs) from three narcoleptic patients were subsequently included. Human embryonic kidney cells were tran-
siently transfected with human HCRTR2, incubated with patients’ sera for 1 hr at 1:20 dilution and then fixed. Binding of  antibodies was detected by fluorescently 
labeled secondary antibodies to human immunoglobulin G (IgG) and the different IgG subclasses. A nonlinear visual scoring system was used from 0 to 4; 
samples scoring ≥1 were considered positive.
Results: Only 3 (5%) of  61 patients showed a score ≥1, one with IgG1- and two with IgG3-antibodies, but titers were low (1:40–1:100). CSFs from these 
patients were negative. The three positive patients included one NT1 case with associated psychotic features, one NT2 patient, and an NT1 patient with normal 
hypocretin CSF levels.
Conclusions: Low levels of  IgG1 or IgG3 antibodies against HCRTR2 were found in 3 of  61 patients with narcolepsy, although only 1 presented with full-blown 
NT1. HCRTR2-Abs are not common in narcolepsy unrelated to vaccination.
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INTRODUCTION
Narcolepsy is a rare central disorder of hypersomnolence, 
mainly characterized by excessive daytime sleepiness (EDS) 
and cataplexy, which is a sudden loss of muscle tone triggered 
by strong emotions. Other features include hallucinations at 
sleep onset and awakening and sleep paralysis.1 Two subtypes 
of the disease are recognized, narcolepsy type 1 (NT1) and 
narcolepsy type 2 (NT2). NT1 is associated with loss of hypo-
cretin (HCRT)-secreting neurons in the lateral hypothalamus2–4 
without a parallel loss of neurons expressing melanin-concen-
trating hormone3,4 The strong HLA DRB1*06:02 association5,6 
suggests an autoimmune-driven process.7 Both NT2 and NT1 
are characterized by EDS and sleep-onset rapid eye movement 
periods. However, in NT2 cases, the hypocretin 1 cerebrospinal 
fluid (CSF) levels should be above the cutoff value of 110 pg/mL 
or >1/3 of the mean control values,8 and the HLA DRB1*06:02 
association is found in only 40%–50%9,10 of patients. Therefore, 
the pathophysiology of NT2 remains elusive.
The role of autoimmunity has been strengthened by the 
increased rates of narcolepsy onset in children following 
Streptococcus pyogenes11 and influenza A H1N1 infections12 
as well as after exposure to selected H1N1 vaccine prepara-
tions such as Pandemrix®.13 These observations suggest that, 
in an appropriate genetic setting, exposure to some infections 
can lead, through unknown mechanisms, to a hypocretin neu-
ron-specific autoimmune destruction. There is no evidence 
for disease-specific antibodies directed against neuronal14–19 
or nonneuronal autoantigens20 in any form of narcolepsy, but 
a recent study noted homology between the H1N1 influenza 
virus nucleoprotein A and the first extracellular domain of the 
hypocretin receptor 2 (HCRTR2). Antibodies to the HCRTR2 
(HCRTR2-Abs) were found in 85.0% (17 of 20) of NT1 
patients with a history of Pandemrix vaccination, although 
also in up to 34.7% (16 of 46) of the non-narcolepsy con-
trol groups.21 The diagnostic and pathological significance of 
the antibodies in vaccine-related narcolepsy is, therefore, not 
clear.22 Moreover, other narcolepsy patient groups were not 
investigated.
We used a live cell-based assay (CBA) approach, as now 
used in many diagnostic antibody tests,23,24 to establish 
an assay for HCRTR2-Abs and tested sera from patients 
with narcolepsy, other sleep disorders, healthy, and disease 
controls.
MATERIALS AND METHODS
Patients and Serum Samples
Sera from 61 narcolepsy patients (41 adults and 20 children), 
including 50 patients with NT1 and 11 patients with NT2, 22 
patients with other sleep disorders (11 patients with Idiopathic 
Hypersomnia [IH] and 11 patients complaining of EDS with 
normal sleep studies [subjective-EDS, sEDS]), 15 healthy con-
trols (HC), and 93 disease controls (39 epileptic and 54 patients 
with known positivity for neuronal surface antigens, i.e., AQ4, 
CASPR2, LGI1, and MOG) were studied. Sleep disorders and 
epileptic patients’ sera and CSFs (n = 3) were retrieved from the 
Sleep Center of the Neurologic clinic of Bologna. Antibody-
positive and healthy control sera, all anonymized, were 
retrieved from the Neuroimmunology laboratory of the Nuffield 
Department of Clinical Neurosciences. Narcolepsy and IH were 
diagnosed accordingly to the International Classification of 
Sleep Disorders, 3rd edition.8 Subjective daytime sleepiness 
was assessed using the Epworth Sleepiness Scale. All patients 
underwent  Multiple Sleep Latency Test (MSLT) the day after 
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48 hr continuous polysomnography. CSF HCRT-1 levels and 
HLA status at locus DQB1*0602 were available in all narcolep-
tic and other sleep disorder patients. Local ethical committee 
approved the study, and written informed consent was obtained 
from all study participants.
Plasmid Construct and Transfection of Human Embryonic 
Kidney Cells
Human HCRTR2 complementary DNA in the pcDNA3.1(−) mam-
malian expression vector was used for transient transfection of 
human embryonic kidney (HEK) 293 cells. Briefly, HEK293 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma®) supplemented with 10% fetal calf serum (Biowest®) and 
1% each of penicillin G and streptomycin in 175-cm3 tissue cul-
ture flasks at 37°C, 5% CO
2
; 4.6 × 105 HEK cells were seeded 
into 6-well plates containing four borosilicate glass coverslips 
(13 mm, VWR International®) previously coated with poly-L-ly-
sine. Twenty-four hours after seeding, at about 60% of confluence, 
the cells were transiently transfected with the HCRTR2-encoding 
plasmid. A total of 3 µg of DNA was diluted in 50 µL DMEM, 
0.82 µL of 20% glucose, and 1.5 µL of polyethylenimine per well. 
After 12–16 hr of incubation (37°C), the media was replaced and 
cells cultured for a further 24 hr before use.
HCRTR2-IgG CBA
A CBA for the HCRT2-Abs was performed as for other 
routine antibody assays in the Oxford diagnostic labora-
tory. Briefly, coverslips were incubated either with commer-
cial goat anti-HCRTR2 antibody (ab65093, 1:300 dilution; 
Abcam) or with patient or control serum (1:20) or CSF 
(1:3), in incubation buffer (1% bovine serum albumin and 
20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid) in DMEM) at room temperature for 1 hr. After 
washing, the cells were fixed with 4% paraformaldehyde in 
phosphate-buffered saline for 10 min at room temperature, 
washed, and incubated with the appropriate secondary anti-
bodies: donkey antigoat IgG (H+L) Alexa Fluor® 568-conju-
gated antibody (1:750) or goat antihuman immunoglobulin G 
(IgG; (H+L)-Alexa Fluor® 568-conjugated antibody (1:750; 
ThermoFisher scientific).
Table 1—Demographics, CSF Hcrt-1 Levels, and HLA DQB1*0602 Status.




Age at EDS  
onset, years,  
mean ± SD
Time to  
cataplexy, years,  
mean ± SD
Time to sampling,  
years, mean ± SD













1 F 14 Simultaneous  
with EDS onset
1 - <110 Psychosis
a 1 F 16 1 7 - Normal HCRTR2-Ab  
positive (IgG1 > 
IgG2) (Patient 2)
NT2 5 3/2 27.5 ± 14.1 - 7.7 ± 5.7 - Normal
a 1 F Childhood - - - Normal HCRTR2-Ab 
positive (IgG3) 
(Patient 3)
4 2/2 12 ± 4.3 - 8 ± 8.1 + Normal
1 M 6 - 18 + <110
IH 10 3/7 21.1 ± 16.4 - 20.2 ± 17.3 - Normal
1 F 20 - 11 + Normal
sEDS 9 4/5 20.5 ± 13.7 - 10.4 ± 8.1 - Normal
2 1/1 27.5 ± 10.6 - 8.5 ± 9.1 + Normal
HC 15 - - - - NA NA
DS 39 - - - - NA NA
AI 54 - - - - NA NA
Abbreviations: Hcrt-1, hypocretin 1; Normal levels >200 pg/ml; NA, not available; DS, disease controls; AI, autoimmune controls.*
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To confirm the presence of IgG antibodies, goat anti-human 
IgG-Fc (1:750) or mouse anti-human IgG1, IgG2, IgG3, or 
IgG4 (Sigma; 1:50) were used followed by donkey anti-goat 
IgG-Alexa Fluor® 568 goat or anti-mouse IgG-Alexa Fluor® 
568 conjugated secondary antibody (1:750). The presence of 
immunoglobulin M (IgM) antibodies was assessed by goat 
anti-human IgM Alexa Fluor® 568-conjugated antibody 
(Thermo Scientific, #31125; 1:750).
Immunofluorescence Analysis
Coverslips were coded, and the immunofluorescence was 
scored for the frequency and intensity of surface antibody 
binding, using a visual nonlinear scoring system from 0 to 4, 
as described previously.25 All samples were tested twice, and 
any serum showing a score ≥ 0.5 was repeated at least 3 times. 
Samples scoring ≥1 were considered positive and evaluated for 
specificity by testing against at least one other antigen.
Statistical Analysis
Frequencies are expressed as percentages. Mean, SD, and SE 
were calculated and data were plotted using GraphPad PRISM 6.
RESULTS
Clinical Data
The clinical data, the HCRT-1 levels, and DQB1*0602 status 
are given in the Table 1. Among narcolepsy patients, 18 (7 chil-
dren) were considered to have had an acute onset (≤3 months 
elapsed between EDS and cataplexy onset) and in all but 1 
cataplexy and EDS appeared in the same month. The interval 
between onset and serum sampling, however, was highly varia-
ble (see Table 1), and only four acute patients were sampled at 2 
(3 patients) and 4 (1 patient) months after onset.
The narcolepsy cohort included rare cases with uncommon 
combinations of clinical features, HLA status and CSF HCRT-1 
levels, as well as atypical cases, including patients with NT1 
Figure 1—(A) Representative image of  a cell-based assay (CBA) using the commercial antibody or (B) a positive patient serum (Patient #1). 
Binding of  antibodies is scored on a scale from 0 to 4 with values 1 and above considered positive.24 Note that the intensity of  binding is similar 
between A and B, but the commercial antibody has been diluted 300-fold and the patient serum only 20-fold. (C) Screening of  the 191 serum 
samples detected only 3 narcoleptic patients with scores of  1 or above. (D). Serial dilutions of  the sera showed that the end point dilutions, 
giving a score of  1, were only 1:40 or 1:100 indicating low antibody titers. The results are given as mean ± standard error of  mean of  3 or more 
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and associated psychosis (Table 1). One patient presented NT1 
after receiving the Focetria® H1N1 vaccine.
HCRTR2 Antibody Detection
HCRTR2 was expressed on the surface of the live HEK cells 
as shown by strong binding of the commercial antibody against 
the extracellular domain of the receptor (Figure 1A). All control 
sera were negative for binding to HCRTR2. Only 3 (5%) of 61 
narcolepsy sera showed a positive score of ≥1 (Figure 1B, C). 
Serum dilutions were performed in the three sera scoring ≥1, 
and none of them reached a score of 1 at a dilution beyond 
1:100 (Figure 1 D). CSFs from the three positive patients were 
negative.
The presence of IgG antibodies was confirmed using an 
IgG-Fc secondary antibody and also by determining the IgG 
subclasses in the three positive patients (Figure 2A, B). IgG3 
HCRTR2-Abs were present in two patients (one patient with 
NT1 and one patient with NT2). The third patient (NT1) had 
IgG1 and IgG2 HCRTR2-Abs. IgM antibodies were negative in 
each case (data not shown).
The clinical features of these three patients are summarized 
in Table 1. Patient #1 presented with a progressive psychiatric 
Figure 2—The three positive sera were retested for immunoglobulin G (IgG) using a IgG-specific anti-IgG Fc antibody and for the different IgG 
subclasses. Two patients had mainly IgG3 (A, C Patients #1 and 2) and one mainly IgG1 and IgG2 (B, C Patient #3). The results are given as 
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disorder with severe psychotic features after the diagnosis of 
NT1. Patient #2 presented at age 16 with severe and progres-
sively worsening EDS, daily nightmares, and rare episodes 
of sleep paralysis. From age 17, she developed episodes of 
muscle tone loss induced by emotions. Her MSLT (performed 
twice) was typical for the diagnosis of narcolepsy, but CSF 
hypocretin-1 levels were normal and the patient did not carry 
the HLA DQB*06:02. Although this is atypical, the clear-
cut cataplexy, the typical MSLT and clinical history, led to 
a diagnosis of NT1. This was further supported by the good 
response of cataplexy to venlafaxine and subsequently to 
sodium oxybate treatment. Patient #3 presented with EDS 
since childhood; she never experienced cataplexy, and hypo-
cretin CSF levels were normal, but her MSLT supported the 
diagnosis of NT2.
DISCUSSION
There has been much interest in looking for antibodies to 
potential neuronal targets in narcolepsy, and a recent study 
identified autoantibodies against the HCRTR2 in patients 
with post-Pandemrix® narcolepsy. We established a CBA to 
detect these antibodies, but only 3 (5%) narcolepsy patients 
had IgG antibodies to HCRTR2. Moreover, the titers were 
low in all 3, and no HCRTR2-Abs were found in their CSFs. 
Only one of three had classical NT1 and that patient also had 
psychosis. Tanaka et al.17 also found a low proportion (5 of 
181 patients, 4 NT1 and 1 NT2) of patients with antibodies 
immunoprecipitating [35S]-HCRTR2. Thus, HCRTR2-Abs in 
patients with idiopathic narcolepsy appear to be rare. This, 
together with the low titers in serum and the absence of CSF 
antibodies, which are usually present in patients with typical 
antibody-mediated diseases,23 suggest that they may not be 
clinically relevant.
There are, however, other possible reasons for the low titers 
and the absence in the CSF. None of the three patients with 
HCRTR2-Abs was assessed close to disease onset, a time at 
which the initiating immune response might be more evident. 
The absence in CSF may be related to the relatively low titers 
found in the serum where total IgG levels and most systemic 
antibodies are typically 300–400 times higher than those in 
the CSF.
Ours and Tanaka and colleagues’17 results contrast with the 
much higher rate (85%) reported in patients post-Pandemrix® 
vaccination, although also in 34.7% controls.21 Our results 
could reflect different methodologies, since we used a live-
cell assay with visual inspection of the binding, which allows 
to exclude nonspecific staining, whereas the Pandemrix® study 
used a cell-based enzyme-linked immunosorbent assay21 based 
on a colorimetric reaction. The different frequency may suggest 
a major role of these antibodies in vaccine-related narcolepsy 
but not in idiopathic cases or at least not in typical patients. 
Indeed, all our positives were atypical, as one presented NT1 
and psychosis and two were DQB1*0602 negative, including 
one patient initially diagnosed with NT2 who subsequently 
developed cataplexy, despite normal HCRT-1 CSF levels. Rare 
cases of narcolepsy-like syndromes, often atypical, have been 
observed in the course of antibody-mediated disorders which in 
turn can be associated with low HCRT-1 levels, suggestive of 
a specific vulnerability of the hypocretin neurons independent 
of the HLA status.26,27 Considering the high frequency of the 
DQB1*0602 allele in narcolepsy, the finding of antibodies in 
two HLA-negative patients supports a phenomenon occurring 
only in a rare subgroup of patients, which may be unrelated to 
classical narcolepsy.
Moreover, a major question regarding HCRTR2-Abs relates 
to whether they could be responsible for the loss of the HCRT-
producing neurons in narcolepsy NT1 and where they might 
act in the brain. The pathogenic potential of autoantibodies is 
determined not only by their titers but also by their isotype. 
IgG1 and IgG3 are the most efficient in promoting C1q dep-
osition and complement-dependent cytotoxicity. Therefore, 
if these antibodies are able to access the brain parenchyma, 
they could bind to and cause complement-mediated damage to 
HCRTR2-expressing cells. One would need to postulate, how-
ever, that the hypocretin neurons, which appear to be selec-
tively destroyed in typical narcolepsy,3,4 express autoreceptors 
making the cells vulnerable to the effects of the antibodies. 
This is controversial; Yamanaka and coworkers, using a neuro-
physiological/immunoelectron microscopic approach, found 
that orexin neurons are directly and indirectly activated by 
hypocretin via the HCRTR2.28 By contrast, however, Vassalli 
et al. failed to demonstrate the expression of HCRTR2 on 
mouse hypocretin neurons.22 Alternatively, since hypocre-
tin neurons project widely in the brain where they modulate 
several crucial functions,29 such as sleep and wake, feeding 
behavior and energy homeostasis, autonomic function, and 
reward system regulation, it is possible that the neuronal 
damage is not limited to the hypocretin neurons themselves 
but also affects other neurons that receive the hypocretin sig-
nals via HCRTR1 and HCRTR2. One postmortem narcolepsy 
study30 suggested that gliosis was not restricted to the lateral 
hypothalamus which would be consistent with more wide-
spread expression of an autoantigen. Until these issues have 
been resolved, the significance of any HCRT2-Abs, even in 
a subset of narcolepsy patients, needs to be interpreted with 
caution.
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